Not all diagnostics companies are worried at the prospect of the Supreme Court striking down patents on two cancer-related genes "owned" by Myriad (MYGN) in a decision that is due to come in 2013. Quest (DGX) says it could be a "positive development," as it would "open new opportunities to develop new testing services." Myriad, which has spent 17 years and $500M on isolating the "DNA molecules and processes," isn't so sanguine.
Not all diagnostics companies are worried at the prospect of the Supreme Court striking down...
From other sites
Video at CNBC.com (Sep 15, 2015)
at CNBC.com (Oct 17, 2014)
at CNBC.com (Aug 13, 2014)
at CNBC.com (Aug 12, 2014)
at CNBC.com (Apr 11, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs